GLOBAL TRAZODONE HYDROCHLORIDE (API) MARKET 2019 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2024
- Id : RNR-264797
- Category : Pharma Healthcare
- Publish Date : Apr-19
- Publisher : Research-N-Reports
- Pages : 123
- Format : PDF
Trazodone, a phenylpiperazine?triazolopyridine antidepressant, was originally discovered and developed in Italy in the 1970s by Angelini research laboratories. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety and depression. Like most antidepressants, trazodone has also been used in limited numbers of patients to treat panic disorder, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, enuresis (bed-wetting), eating disorders such as bulimia nervosa, cocaine dependency, and the depressive phase of bipolar (manic-depressive) disorder. It should be noted, however, that trazodone has not received official approval from the United States Food and Drug Administration (FDA) for these secondary uses. Scope of the Report: Only few manufacturers can produce trazodone hydrochloride (API) in USA. Teva, the Israeli company, has a production base in the United States, dominates the market with the production market share of 92.98% in 2015 The price of trazodone hydrochloride (API) has a overall upward trend from 2011 to 2016, with a little decrease in 2012 and 2015. The average price of trazodone hydrochloride (API) is about 218 USD/Kg in 2015. The average product profit margin is about 55.82% in 2015, and it also experienced fluctuations in recent years. The worldwide market for Trazodone Hydrochloride (API) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Trazodone Hydrochloride (API) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Manufacturers, this report covers - Teva - Angelini - Mylan - Fermion - The Piramal Group Market Segment by Regions, regional analysis covers - North America (United States, Canada and Mexico) - Europe (Germany, France, UK, Russia and Italy) - Asia-Pacific (China, Japan, Korea, India and Southeast Asia) - South America (Brazil, Argentina, Colombia etc.) - Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers - Trazodone Hydrochloride (API) - Others Market Segment by Applications, can be divided into - Antidepression - Anxiolytic - Hypnotic - Others The content of the study subjects, includes a total of 15 chapters: Chapter 1, to describe Trazodone Hydrochloride (API) product scope, market overview, market opportunities, market driving force and market risks. Chapter 2, to profile the top manufacturers of Trazodone Hydrochloride (API), with price, sales, revenue and global market share of Trazodone Hydrochloride (API) in 2017 and 2018. Chapter 3, the Trazodone Hydrochloride (API) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Trazodone Hydrochloride (API) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019. Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019. Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019. Chapter 12, Trazodone Hydrochloride (API) market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024. Chapter 13, 14 and 15, to describe Trazodone Hydrochloride (API) sales channel, distributors, customers, research findings and conclusion, appendix and data source.